ADC Biotechnology said it is developing a new downstream bioconjugation method that will present a new paradigm in antibody drug conjugate (ADC) development and manufacturing. In contrast to the existing approaches, which undertake bioconjugation after both the mAb and cytotoxic have been manufactured, this new approach moves the conjugation step into the later stages of the downstream processing (DSP), with conjugation and antibody purification carried out concurrently. “The major bene...